Basque biotech HAWK Biosystems raises €3.5 million in Inveready-led round

The story so far, in brief; the legwork, and the full article, stay with the original outlet.

HAWK Biosystems, a Basque biotech in precision cancer diagnostics, has raised €3.5 million. Inveready led, with the EIC Fund, the Basque Fund and others alongside, taking its total since founding to about €12.5 million.

Its QF-Pro platform tests whether the relevant proteins are really binding inside tumour cells, not just present, which for PD-1 and PD-L1 helps predict who responds to immunotherapy. Being there and doing something are different things.

First products came out in 2025; the company expects about €1 million in 2026 revenue. The money goes to pharma work, EU and US expansion, and a first clinical test in 2027.